Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
406 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
GlaxoSmithKline Plc - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'GlaxoSmithKline Plc - Product Pipeline Review - 2016', provides an overview of the GlaxoSmithKline Plc's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by GlaxoSmithKline Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of GlaxoSmithKline Plc - The report provides overview of GlaxoSmithKline Plc including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses GlaxoSmithKline Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features GlaxoSmithKline Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate GlaxoSmithKline Plc's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for GlaxoSmithKline Plc - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding GlaxoSmithKline Plc's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 8 GlaxoSmithKline Plc Snapshot 9 GlaxoSmithKline Plc Overview 9 Key Information 9 Key Facts 9 GlaxoSmithKline Plc - Research and Development Overview 10 Key Therapeutic Areas 10 GlaxoSmithKline Plc - Pipeline Review 22 Pipeline Products by Stage of Development 22 Pipeline Products - Monotherapy 23 Pipeline Products - Combination Treatment Modalities 24 Pipeline Products - Partnered Products 25 Pipeline Products - Out-Licensed Products 28 GlaxoSmithKline Plc - Pipeline Products Glance 30 GlaxoSmithKline Plc - Late Stage Pipeline Products 30 GlaxoSmithKline Plc - Clinical Stage Pipeline Products 33 GlaxoSmithKline Plc - Early Stage Pipeline Products 39 GlaxoSmithKline Plc - Unknown Stage Pipeline Products 43 GlaxoSmithKline Plc - Drug Profiles 44 gepirone hydrochloride ER 44 GSK-257049 46 GSK-2696273 50 mepolizumab 51 melanoma lysate vaccine 54 (fluticasone furoate + umeclidinium bromide + vilanterol trifenatate) 56 (fluticasone furoate + vilanterol trifenatate) 58 (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine 60 albiglutide 61 ambrisentan 64 AS15 + recMAGE-A3 66 belimumab 68 bupropion hydrochloride ER 72 Ebola [Zaire] vaccine 73 fluticasone furoate 76 GSK-1437173A 79 inotersen sodium 81 KD-295 82 losmapimod 83 meningococcal [serotype B] vaccine 85 retosiban 87 tafenoquine succinate 88 vilanterol trifenatate 90 zanamivir 92 (batefenterol succinate + fluticasone furoate) 94 (fluticasone furoate + levocabastine hydrochloride) 95 alitretinoin 96 batefenterol 98 CAD-106 100 camicinal 102 dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide 104 danirixin 105 daprodustat 107 fluticasone furoate + umeclidinium bromide 109 gepotidacin mesylate 110 group B Streptococcus (trivalent) vaccine 112 GSK-2189242A 114 GSK-2231392A 115 GSK-2245035 116 GSK-2256098 118 GSK-2269557 120 GSK-2302032A 121 GSK-2315698 + GSK-2398852 122 GSK-2330672 123 GSK-2339345 124 GSK-239512 125 GSK-2586881 126 GSK-2696274 127 GSK-2696275 128 GSK-2789869A 129 GSK-2830930A 130 GSK-2838504A 131 GSK-2862277 132 GSK-3003891A 133 GSK-3196165 134 GSK-3277511A 136 GSK-692342 137 GSK-933776 139 GVXNSD-133 140 hepatitis C vaccine 1 141 malaria vaccine 142 mapatumumab 144 maribavir 146 meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine 148 otelixizumab 149 respiratory syncytial virus vaccine 151 rilapladib 152 Streptococcal pneumonia vaccine 3 153 umeclidinium bromide 154 GSK-2302025A 156 GSK-2636771 157 GSK-525762 158 HIV [strains C1086 + TV1] (bivalent) vaccine 159 pazopanib hydrochloride + pembrolizumab 160 TDEN-PIV 161 (amlodipine besylate + rosuvastatin calcium) 162 (candesartan cilexetil + hydrochlorothiazide) 163 (diphtheria + pertussis (acellular) + tetanus) vaccine 164 1790GAHB 165 EcoXyn-4V 166 epelsiban besylate 167 FP-1039 169 GSK-1940029 171 GSK-2130579A 172 GSK-2241658A 173 GSK-2256294 174 GSK-2330811 175 GSK-2618960 176 GSK-2646264 177 GSK-2654909A 178 GSK-2654911A 179 GSK-2789868A 180 GSK-2798745 181 GSK-2800528 182 GSK-2816126 183 GSK-2831781 184 GSK-2849330 185 GSK-2857916 186 GSK-2878175 187 GSK-2879552 188 GSK-2881078 189 GSK-2981278 190 GSK-2981710 191 GSK-2982772 192 GSK-3008348 193 GSK-3117391 194 GSK-3174998 195 GSK-3206640A 196 GSK-3206641A 197 GSK-3389245A 198 hepatitis C vaccine 2 199 HIV vaccine 1 200 HIV vaccine 5 201 IMP-731 202 influenza [strain A/H5N1] vaccine 203 influenza vaccine 2 205 montelukast sodium 206 omipalisib 207 oxytocin 209 RSV-001 210 Staphylococcus aureus vaccine 211 meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 212 BLyS-gel 213 Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis 214 Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa 215 GSK-030 216 GSK-1795091 217 GSK-2041706 218 GSK-214096 219 GSK-2225745 220 GSK-2394002 221 GSK-2656157 222 GSK-2795039 223 GSK-2820151 224 GSK-3039294 225 GSK-3277509A 226 GSK-3277510A 227 GSK-3326595 228 GSK-3359609 229 GSK-6288B 230 GSK-8853 231 GSKJ-4 232 GW-610742 233 HIV vaccine 2 234 influenza vaccine 235 marburg vaccine 236 meningococcal vaccine 2 237 Monoclonal Antibody Conjugate for Oncology 238 raxibacumab 239 Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis 240 Small Molecule 1 for Malaria 241 Small Molecule 1 to Inhibit Histone Methyltransferases for Cancer 242 Small Molecule 2 for Malaria 244 Small Molecule 2 for Tuberculosis 245 Small Molecule 2 to Inhibit Histone Methyltransferases for Cancer 246 Small Molecule 3 to Inhibit Histone Methyltransferases for Cancer 247 Small Molecule for Hypertension and Insulin Resistance 248 Small Molecule to Activate AMPK for Type 2 Diabetes 249 Small Molecule to Agonize S1P1 for Multiple Sclerosis 250 Small Molecules to Inhibit InhA for Tuberculosis 251 Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis 252 staphylococci aureus vaccine 253 Streptococcal pneumonia vaccine 254 TC-2153 255 tuberculosis vaccine 256 Vaccine for Alzheimer's Disease 257 Vaccine for Cancer 258 bacterial vaccine 259 bacterial vaccine 2 260 Drug for Chronic Liver Disease 261 Drugs to Antagonize T-Cell Receptor for Oncology 262 Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis 263 GSK-137647A 264 GSK-343 265 GSK-5959 266 GSKJ-1 267 Proteins for Musculoskeletal Disorders 268 Pseudomonas aeruginosa vaccine 269 Small Molecule for Tuberculosis 270 Small Molecule to Antagonize FFA4 for Undisclosed Indication 271 Small Molecule to Inhibit Histone Deacetylases for Oncology 272 Small Molecules for HIV-1 Infection 273 Small Molecules for Tuberculosis 274 Small Molecules for Undisclosed Indication 275 Small Molecules to Antagonize Folate Receptor for Tuberculosis 276 Small Molecules to Inhibit ATPase family AAA Domain-Containing Protein 2 for Oncology 277 Small Molecules to Inhibit Falcipain for Malaria 278 Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis 279 Small Molecules to Inhibit RNA Polymerase for Hepatitis C 280 (paratyphoid + typhoid) vaccine 281 GlaxoSmithKline Plc - Pipeline Analysis 282 GlaxoSmithKline Plc - Pipeline Products by Target 282 GlaxoSmithKline Plc - Pipeline Products by Route of Administration 295 GlaxoSmithKline Plc - Pipeline Products by Molecule Type 296 GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action 298 GlaxoSmithKline Plc - Recent Pipeline Updates 306 GlaxoSmithKline Plc - Dormant Projects 354 GlaxoSmithKline Plc - Discontinued Pipeline Products 363 Discontinued Pipeline Product Profiles 364 GlaxoSmithKline Plc - Company Statement 376 GlaxoSmithKline Plc - Locations And Subsidiaries 379 Head Office 379 Other Locations & Subsidiaries 379 GlaxoSmithKline Plc - Key Manufacturing Facilities 390 Appendix 391 Methodology 391 Coverage 391 Secondary Research 391 Primary Research 391 Expert Panel Validation 391 Contact Us 391 Disclaimer 392
List of Tables GlaxoSmithKline Plc, Key Information 23 GlaxoSmithKline Plc, Key Facts 23 GlaxoSmithKline Plc - Pipeline by Indication, 2016 25 GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016 36 GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016 37 GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016 38 GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016 39 GlaxoSmithKline Plc - Partnered Products/ Combination Treatment Modalities, 2016 40 GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016 42 GlaxoSmithKline Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016 43 GlaxoSmithKline Plc - Pre-Registration, 2016 44 GlaxoSmithKline Plc - Filing rejected/Withdrawn, 2016 45 GlaxoSmithKline Plc - Phase III, 2016 46 GlaxoSmithKline Plc - Phase II, 2016 47 GlaxoSmithKline Plc - Phase I, 2016 50 GlaxoSmithKline Plc - IND/CTA Filed, 2016 53 GlaxoSmithKline Plc - Preclinical, 2016 54 GlaxoSmithKline Plc - Discovery, 2016 56 GlaxoSmithKline Plc - Unknown, 2016 57 GlaxoSmithKline Plc - Pipeline by Target, 2016 296 GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016 309 GlaxoSmithKline Plc - Pipeline by Molecule Type, 2016 310 GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action, 2016 312 GlaxoSmithKline Plc - Recent Pipeline Updates, 2016 320 GlaxoSmithKline Plc - Dormant Developmental Projects,2016 368 GlaxoSmithKline Plc - Discontinued Pipeline Products, 2016 377 GlaxoSmithKline Plc, Other Locations 393 GlaxoSmithKline Plc, Subsidiaries 393 GlaxoSmithKline Plc, Key Manufacturing Facilities 404
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.